Literature DB >> 11052071

Total syntheses of the Securinega alkaloids (+)-14,15-dihydronorsecurinine, (-)-norsecurinine, and phyllanthine.

G Han1, M G LaPorte, J J Folmer, K M Werner, S M Weinreb.   

Abstract

A new strategy for enantiospecific construction of the Securinega alkaloids has been developed and applied in total syntheses of (+)-14,15-dihydronorsecurinine (8), (-)-norsecurinine (6), and phyllanthine (2). The B-ring and C7 absolute stereochemistry of these biologically active alkaloids originated from trans-4-hydroxy-L-proline (10), which was converted to ketonitrile 13 via a high-yielding eight-step sequence. Treatment of this ketonitrile with SmI2 afforded the 6-azabicyclo[3.2.1]octane B/C-ring system 14, which is a key advanced intermediate for all three synthetic targets. Annulation of the A-ring of (-)-norsecurinine (6) with the required C2 configuration via an N-acyliminium ion alkylation was accomplished using radical-based amide oxidation methodology developed in these laboratories as a key step, providing tricycle 33. Annulation of the D-ring onto alpha-hydroxyketone 33 with the Bestmann ylide 45 at 12 kbar gave (+)-14,15-dihydronorsecurinine (8). In the securinine series, the D-ring was incorporated using an intramolecular Wadsworth-Horner-Emmons olefination of phenylselenylated alpha-hydroxyketone 47. The C14,15 unsaturation was installed late in the synthesis by an oxidative elimination of the selenoxide derived from tetracyclic butenolide 50 to give (-)-norsecurinine (6). The A-ring of phyllanthine (2) was formed from hydroxyketone 14 using a stereoselective Yb(OTf)3-promoted hetero Diels-Alder reaction of the derived imine 34 with Danishefsky's diene, affording adduct 35. Conjugate reduction and stereoselective equatorial ketone reduction of vinylogous amide 35 provided tricyclic intermediate 36, which could then be elaborated in a few steps to stable hydroxyenone 53 via alpha-selenophenylenone intermediate 52. The D-ring was then constructed, again using an intramolecular Wadsworth-Horner-Emmons olefination reaction to give phyllanthine (2).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052071     DOI: 10.1021/jo000260z

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  7 in total

1.  An Enantioselective Approach to the Securinega Alkaloids: The Total Synthesis of (+)-Norsecurinine and (+)-Allonorsecurinine.

Authors:  Matthew R Medeiros; John L Wood
Journal:  Tetrahedron       Date:  2010-06-26       Impact factor: 2.457

2.  Enantioselective total syntheses of (-)-palau'amine, (-)-axinellamines, and (-)-massadines.

Authors:  Ian B Seiple; Shun Su; Ian S Young; Akifumi Nakamura; Junichiro Yamaguchi; Lars Jørgensen; Rodrigo A Rodriguez; Daniel P O'Malley; Tanja Gaich; Matthias Köck; Phil S Baran
Journal:  J Am Chem Soc       Date:  2011-08-23       Impact factor: 15.419

3.  6-Azabicyclo[3.2.1]octanes Via Copper-Catalyzed Enantioselective Alkene Carboamination.

Authors:  Barbara J Casavant; Azade S Hosseini; Sherry R Chemler
Journal:  Adv Synth Catal       Date:  2014-08-11       Impact factor: 5.837

Review 4.  Challenges in the synthesis of a unique mono-carboxylic acid antibiotic, (+)-zincophorin.

Authors:  Zhenlei Song; Andrew G Lohse; Richard P Hsung
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

5.  Factors Controlling the Diels-Alder Reactivity of Hetero-1,3-Butadienes.

Authors:  Song Yu; Hans M de Bruijn; Dennis Svatunek; Trevor A Hamlin; F Matthias Bickelhaupt
Journal:  ChemistryOpen       Date:  2018-11-26       Impact factor: 2.911

6.  Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways.

Authors:  Liang Yu; Meng Wang; Yang Yang; Fengdan Xu; Xu Zhang; Fei Xie; Lin Gao; Xiangzhi Li
Journal:  PLoS Comput Biol       Date:  2021-02-09       Impact factor: 4.475

7.  Collective total synthesis of C4-oxygenated securinine-type alkaloids via stereocontrolled diversifications on the piperidine core.

Authors:  Sangbin Park; Gyumin Kang; Chansu Kim; Dongwook Kim; Sunkyu Han
Journal:  Nat Commun       Date:  2022-09-02       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.